Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma.

ABSTRACT:

Aim

Metastatic melanoma patients were treated with patient-specific vaccines consisting of autologous dendritic cells loaded with antigens from irradiated cells from short-term autologous tumor cell lines.

Patients & methods

A total of 72 patients were enrolled in a single-arm Phase I/II (NCT00948480) trial or a randomized Phase II (NCT00436930).

Results

Toxicity was minimal. Median overall survival (OS) was 49.4 months; 5-year OS 46%. A 5-year OS was 72% for 18 recurrent stage 3 without measurable disease when treated and 53% for 30 stage 4 without measurable disease when treated. A total of 24 patients with measurable stage 4 when treated (median of four prior therapies) had an 18.5 months median OS and 46% 2-year OS.

Conclusion

This dendritic cell vaccine wa

SUBMITTER: Dillman RO 

PROVIDER: S-EPMC6688559 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature